Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Enlivex ( (ENLV) ) has shared an update.
On September 11, 2025, Enlivex Therapeutics announced positive results from its Phase IIa trial of Allocetra™ for knee osteoarthritis, demonstrating significant improvements in pain and function. The company plans to advance to a Phase IIb trial in 2026, with six-month data expected in November 2025. These results position Enlivex as a strong candidate for partnerships and funding opportunities, potentially transforming treatment options for the growing population affected by KOA.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy. The company is based in Nes Ziona, Israel, and is engaged in developing therapies for conditions such as knee osteoarthritis (KOA).
Average Trading Volume: 546,365
Technical Sentiment Signal: Sell
Current Market Cap: $24.22M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.